Alkermes plc (ALKS)
| Market Cap | 4.90B |
| Revenue (ttm) | 1.51B |
| Net Income (ttm) | 348.45M |
| Shares Out | 165.08M |
| EPS (ttm) | 2.08 |
| PE Ratio | 14.36 |
| Forward PE | 18.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,368,215 |
| Open | 30.30 |
| Previous Close | 30.04 |
| Day's Range | 29.53 - 30.51 |
| 52-Week Range | 25.17 - 36.45 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 42.21 (+42.22%) |
| Earnings Date | Oct 28, 2025 |
About ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su... [Read more]
Financial Performance
In 2024, Alkermes's revenue was $1.56 billion, a decrease of -6.36% compared to the previous year's $1.66 billion. Earnings were $367.07 million, an increase of 3.18%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ALKS stock is "Strong Buy." The 12-month stock price target is $42.21, which is an increase of 42.22% from the latest price.
News
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz
On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.
Alkermes plc (ALKS) M&A Call Transcript
Alkermes plc (NASDAQ:ALKS) M&A Call October 22, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO ...
Alkermes to acquire Avadel for up to $2.1 billion
Alkermes said on Wednesday it will acquire Avadel Pharmaceuticals for up to $2.1 billion gaining access to the company's approved excessive daytime sleepiness drug.
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO...
Alkermes to Report Third Quarter Financial Results on October 28, 2025
DUBLIN , Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m.
Alkermes Appoints Joshua Reed as Chief Financial Officer
DUBLIN , Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept.
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/o...
Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)
Alkermes plc (NASDAQ:ALKS) World Sleep Congress 2025 Conference September 8, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Rich...
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – – Ali...
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity,...
Alkermes: A More Than Solid Quarter
Alkermes plc is a mid-cap and quite profitable commercial-stage biopharma company, and we are revisiting it today for the first time in a year. The company just reported Q2 financial results, with pro...
Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call July 29, 2025 8:00 AM ET Company Participants Blair C. Jackson - Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO C.
Alkermes plc Reports Second Quarter 2025 Financial Results
— Second Quarter Revenues of $390.7 Million — — GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — — Company Reiterates 2025 Financial Expectations — — Alkerme...
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton De...
Alkermes to Report Second Quarter Financial Results on July 29, 2025
DUBLIN , July 15, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
DUBLIN , June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Co...
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN , June 2, 2025 /PRNewswire/ -- Alker...
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible
The company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The on...
Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Sandy Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - ...
Alkermes plc Reports First Quarter 2025 Financial Results
— First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company Reiterates 2025 Financial Expectations — DUBLIN , May ...
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
– Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking – – Respondents Cited the Influence of Their Healthcare Providers and t...
Alkermes to Report First Quarter Financial Results on May 1, 2025
DUBLIN , April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
DUBLIN , April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake ...
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
DUBLIN , April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to p...